365 related articles for article (PubMed ID: 18385495)
1. Regulating off-label drug use--rethinking the role of the FDA.
Stafford RS
N Engl J Med; 2008 Apr; 358(14):1427-9. PubMed ID: 18385495
[No Abstract] [Full Text] [Related]
2. Off-label or off-limits?
Ratner M; Gura T
Nat Biotechnol; 2008 Aug; 26(8):867-75. PubMed ID: 18688236
[No Abstract] [Full Text] [Related]
3. The First Amendment and FDA restrictions on off-label uses: the call for a new approach.
Leghorn J; Brophy E; Rother P
Food Drug Law J; 2008; 63(2):391-406. PubMed ID: 18561466
[No Abstract] [Full Text] [Related]
4. Is it a cosmetic, a drug, or both? (Or is it soap?).
Center for Safety and Applied Nutrition/Office of Cosmetics and Colors US Food and Drug Administration
Plast Surg Nurs; 2008; 28(4):195-7. PubMed ID: 19092587
[No Abstract] [Full Text] [Related]
5. Shifting terrain in the regulation of off-label promotion of pharmaceuticals.
Mello MM; Studdert DM; Brennan TA
N Engl J Med; 2009 Apr; 360(15):1557-66. PubMed ID: 19357413
[No Abstract] [Full Text] [Related]
6. The use of Food and Drug Administration--approved medications for unlabeled (off-label) uses. The legal and ethical implications.
Torres A
Arch Dermatol; 1994 Jan; 130(1):32-6. PubMed ID: 8285737
[TBL] [Abstract][Full Text] [Related]
7. The new FDA pregnancy labeling requirements for drugs.
Frederiksen MC
J Midwifery Womens Health; 2011; 56(3):303-7. PubMed ID: 21535377
[TBL] [Abstract][Full Text] [Related]
8. Marketing off-label uses to physicians: FDA's draft (mis)guidance.
Gass A; Wilson J
Am J Bioeth; 2008 Mar; 8(3):1-3. PubMed ID: 18570084
[No Abstract] [Full Text] [Related]
9. Forbidden and Permitted Statements about Medications--Loosening the Rules.
Avorn J; Sarpatwari A; Kesselheim AS
N Engl J Med; 2015 Sep; 373(10):967-73. PubMed ID: 26332553
[No Abstract] [Full Text] [Related]
10. Highlights and a hidden hazard--the FDA's new labeling regulations.
Avorn J; Shrank W
N Engl J Med; 2006 Jun; 354(23):2409-11. PubMed ID: 16760439
[No Abstract] [Full Text] [Related]
11. Presumption of innocence: FDA's authority to regulate the specifics of prescription drug labeling and the preemption debate.
Dorfman HL; Quinn VM; Brophy EA
Food Drug Law J; 2006; 61(4):585-622. PubMed ID: 17180765
[No Abstract] [Full Text] [Related]
12. FDA proposes new rules for off-label use of prescription drugs. Food and Drug Administration.
Baker R
BETA; 1998 Jul; ():8-9. PubMed ID: 11365570
[TBL] [Abstract][Full Text] [Related]
13. From off-label prescribing towards a new FDA.
Tabarrok A
Med Hypotheses; 2009 Jan; 72(1):11-3. PubMed ID: 18835103
[TBL] [Abstract][Full Text] [Related]
14. The case for preemption of prescription drug failure-to-warn claims.
Kim CH
Food Drug Law J; 2007; 62(2):399-422. PubMed ID: 17632969
[No Abstract] [Full Text] [Related]
15. Off-label prescribing. Legal implications.
Henry V
J Leg Med; 1999 Sep; 20(3):365-83. PubMed ID: 10530051
[No Abstract] [Full Text] [Related]
16. FDA proposes more stringent pediatric-use labeling of prescription drug products.
Clin Pharm; 1993 Jan; 12(1):6. PubMed ID: 8428434
[No Abstract] [Full Text] [Related]
17. FDA proposes more stringent pediatric-use labeling of prescription drug products.
Am J Hosp Pharm; 1993 Jan; 50(1):13, 16. PubMed ID: 8427271
[No Abstract] [Full Text] [Related]
18. To inform or persuade? Direct-to-consumer advertising of prescription drugs.
Berndt ER
N Engl J Med; 2005 Jan; 352(4):325-8. PubMed ID: 15673797
[No Abstract] [Full Text] [Related]
19. Making it easier to read prescriptions.
Farley D
FDA Consum; 1995; 29(6):25-7. PubMed ID: 10143448
[No Abstract] [Full Text] [Related]
20. Regulatory controversy surrounding ipecac use and misuse.
Brushwood DB; Tietze KJ
Am J Hosp Pharm; 1986 Jan; 43(1):157-61. PubMed ID: 2869686
[No Abstract] [Full Text] [Related]
[Next] [New Search]
